Tag:
Zalbin
Latest Headlines
Latest Headlines
Novartis takes $590M hit as HGS ditches hep C drug Zalbin
Human Genome Sciences and its partner Novartis took one look at the FDA's complete response letter for the hepatitis C treatment Zalbin and just walked away, shelving any further plans for the
HGS's hep C drug Zalbin hits an FDA hurdle
Human Genome Sciences' hopes of gaining quick FDA approval of its hepatitis C drug Zalbin appear to be foundering. The Rockville, MD-based developer released a statement this morning that the FDA had
Zalbin data underscore new option for hep C patients
Human Genome Sciences helped burnish the reputation of its experimental therapy Zalbin as an alternative option for hepatitis C patients. HGS reported that a mid-stage trial demonstrated that a
HGS seeks Zalbin OK as analysts revive buyout buzz
Just before checking out for the Thanksgiving vacation, Human Genome Sciences announced that it had filed for FDA approval of its promising hepatitis C drug Zalbin, adding that Novartis is expected
